Members of the ATP-binding cassette (ABC) transporter superfamily are mutated to cause diseases that include cystic fibrosis, hyperinsulinemia, adrenoleukodystrophy, Stargardt disease and multidrug resistance. We recently isolated a novel human member of ABC transporter superfamily as the candidate transporter for the glucuronide and glutathione-conjugated antitumor agents, and found it highly homologous to the rat cmoat gene. Consistent with recent findings of defects in the homologous cmoat gene in two rat models of hyperbilirubinemia (TR -and Eisai), we report two deletions and a missense mutation in the active transport family signature region in the gene in patients with hyperbilirubinemia II/Dubin-Johnson syndrome (DJS; MIM 237500), respectively. These results strongly implicate the cMOAT gene as responsible for the defects in DJS patients.
INTRODUCTION
Hyperbilirubinemia II/Dubin-Johnson syndrome (DJS; MIM 237500), a hereditary disease transmitted as an autosomal recessive trait, is characterized by conjugated hyperbilirubinemia, an increase in the urinary excretion of co-proporphyrin isomer I, deposition of melanin-like pigment in hepatocytes and prolonged retention of sulfobromophthalein, but otherwise normal liver function (1) (2) (3) (4) . The genetic basis of DJS is unknown, but early studies suggested defects in excretion rather than in the import or conjugation of bilirubin.
Hepatobiliary excretion of conjugated bilirubin is mediated by an ATP-dependent transport system, the canalicular multispecific organic anion transporter (cMOAT), located in the apical (canalicular) membrane of hepatocytes (5) (6) (7) . The multidrug resistanceassociated protein (MRP) can also transport glutathione conjugates [leucotriene C 4 (LTC 4 ) and dinitrophenyl glutathione (GS-DNP)] (8, 9) , which are also putative substrates for transport by cMOAT protein, but the expression of the MRP gene in liver is very low (9) . Recently, Paulusma et al. demonstrated that rat cMOAT is a liver-specific homolog of the MRP; they reported that TR -rats, an animal model of DJS, are defective in anion transporter (cMOAT) and found a single nucleotide deletion mutation at nucleotide 1179 in the gene, resulting in reduced mRNA abundance and absence of the protein (10). Ito et al. (11) have reported independently that expression of cmoat is defective in Eisai hyperbilirubinemic rats (EHBR), a second animal model, and found a molecular defect in cmoat in that case as well, a transition mutation (G→A at nucleotide 2564) that creates a premature stop codon.
We recently isolated a novel human member of the ATP-binding cassette (ABC) transporter superfamily as the candidate transporter for the glucuronide and glutathione-conjugated antitumor agents, and found it highly homologous to the rat cmoat gene (12) . Recently, >20 genes for the ABC transporter were found in the expressed sequence tag (EST) databases and their genomic map positions determined (13, 14) . One of these, EST172291 (13), corresponds to the human cMOAT gene (12) by sequence identity and map location. Members of the ABC transporter superfamily (15) are mutated to cause diseases that include cystic fibrosis (16) , hyperinsulinemia (17) , adrenoleukodystrophy (18) , Stargardt disease (19) and multidrug resistance (20) .
These results raised the question of whether the human cMOAT gene is responsible for DJS. The mRNA and genomic DNA encoding the cMOAT gene were analyzed in four DJS patients. We detected a deletion caused by a mutation at a splice site in a patient and also a missense mutation and/or a deletion mutation in the active transport family signature region that is characteristic of nucleotide-binding folds of ABC transporters (15) in three *To whom correspondence should be addressed. Tel: +81 92 642 6100; Fax: +81 92 642 6203; Email: wada@biochem1.med.kyushu-u.ac.jp other patients, strongly suggesting that the mutated cMOAT gene is responsible for the defects in DJS patients.
RESULTS AND DISCUSSION
Using RT-PCR and sequence analysis, we analyzed the entire cMOAT cDNA sequence from four patients that had high concentrations of T (total)-and D (direct)-bilirubin [5.0, 5.2, 1.3 and 1.3 mg/dl for T-and ND (not determined), 3.8, 0.8 and 0.8 mg/ml for D-bilirubin in patients DJ1, DJ7, DJ4 and DJ5, respectively]. Patients DJ4 and DJ5 were brothers, and the others are unrelated. We identified a missense mutation 2302 (C→T) R768W in the active transport family signature (15) present in cDNA of three patients, DJ1, DJ4 and DJ5 (Figs 1 and 2 ). This mutation was homozygous in genomic DNA of the severely affected patient DJ1 and heterozygous in patients DJ4 and DJ5 and their father DJ2 (Fig. 2) . The second alteration, 2272del168, a deletion of 168 nucleotides from 2272 to 2439 in PCR product G, was also detected in cDNA from peripheral blood leukocyte of DJ4 and DJ5 (Figs 1 and 3a) . Sequence, RT-PCR and restriction analyses (loss of the AciI site) of DJ4, DJ5 and their family members showed perfect co-segregation of the mutations with the DJS trait (Figs 2 and 3a) . Patients DJ4 and DJ5 are compound heterozygote for both mutations, whereas parents DJ2 and DJ3, who have both been diagnosed as carriers by urinary excretion of co-proporphyrin I (21), are heterozygotes for one of each mutation, respectively (Figs 2 and 3a) . Their sister DJ6 does not have both mutations (Figs 2 and 3a) . Restriction analysis of RT-PCR product F was also consistent with these results. The product F of an allele corresponding to the deletion mutation 2272del168 is not expected to be detected in DJ3, DJ4 and DJ5, because one of the primers used for amplification of the product F locates in the deleted region described above. As a result, the product with mutation 2302 (C→T) was detected in DJ4 and DJ5, the product with no mutation 2302 (C→T) was detected in DJ3 and DJ6, and the product of both types was detected in DJ2 (Fig.  3b) . The base substitution 2302 (C→T) and the deletion 2272del168 were not detected in any of 50 unrelated controls. RT-PCR analysis of peripheral blood leukocytes also revealed a shorter than expected band with primer pair H in subjects DJ4 and DJ5. However, this deletion, 2748del136, was also detected in some control samples, and proved on sequencing to represent an apparent product of alternative splicing, with one exon skipped. Genomic sequencing of DJ4 and DJ5 revealed no alteration of exon-intron boundaries corresponding to 2748del136.
A third alteration in cDNA, 1669del147, a deletion of 147 nucleotides from 1669 to 1815 in PCR product E, was identified in patient DJ7 (Figs 1 and 4a ). The genomic sequence was determined, including exon-intron boundaries (Fig. 4b) , and revealed that the deletion junction was at an exon-intron boundary. A T→A transition two bases after the 3′ boundary of the corresponding exon (the splice donor site) was identified in genomic DNA isolated from patient DJ7 (Fig. 4b) . No deletion was detected in 50 unrelated controls, and no other change was observed in the cMOAT of patient DJ7 (data not shown).
In contrast to the two animal models for DJS, we observed similar levels of cMOAT mRNA in the liver of patient DJ7 (the only one for whom liver tissue was available) compared with normal liver. The deletion mutation in patient DJ7, and presumably the missense mutation as well, thus most likely affects protein formation or function rather than an absence of transcription. This Figure 1 . The nucleotide sequence of cMOAT cDNA amplified by primer pairs E, F and G. The nucleotide sequence of primer pairs E, F and G are indicated by thick underlining with the characters E5′, E3′, F5′, F3′, G5′, G3′, respectively. Waker A, B and C motif are indicated by underlining with the characters WA, WB and WC, respectively. The C→T transition mutation detected in this study is indicated by a bold letter T below the wild-type sequence C, and the amino acid change W is also shown above the wild-type amino acid R. The deletion mutations detected are indicated by boxes. The nucleotide number from the translation start site is shown on the right.
interpretation of the mutation analysis is supported further by the demonstration of the absence of the canalicular isoform of the MRP in DJS (22) and by the segregation profile of the mutation (Figs 2 and 3a) , which is consistent with the autosomal recessive inheritance of the syndrome (2,4) and the chromosomal location, 10q21, of the human cMOAT gene (12) . During the preparation of this report, Paulusma et al. have reported a nonsense mutation at codon 1066 in another DJS patient (23) . Although this report was not accompanied by genomic analysis data, it further supports the conclusion reached here.
The Walker A, B motif and the active transport family signature, also called the C motif at the nucleotide-binding site, are highly conserved among members of the ABC transporter superfamily, and are important for both ATP binding and hydrolysis. Missense mutation of the active transport family signature, as we found in patients DJ1, DJ4 and DJ5, is also reported in other ABC transporter disorders, including cystic fibrosis and Stargardt disease (19, 24) . As in DJS, the loss of the transporter function is severe but not lethal to the affected cells. In DJS, this combination of features permits the survival of liver The sequencing result indicates that DJ1 is homozygous for the mutation 2302(C→T). DJ4 and DJ5 are brothers and are heterozygous for the mutation, having inherited it from their father DJ2 who is also heterozygous for this mutation. The mother, DJ3, and sister, DJ6, of DJ4 and DJ5 do not have this mutation. Sequencing profiles of the sense strand of only DJ3 (wild-type), DJ4 (heterozygous mutant) and DJ1(homozygous mutant) are presented. (b) Restriction digestion analysis of the genomic region around the mutation 2302(C→T) in DJ1, DJ4, DJ5 and their family members. The mutation 2302(C→T) destroys a naturally occurring AciI restriction site. PCR-amplified genomic DNA (170 bp) was digested with AciI and the products were electrophoresed on a 3% agarose gel. Wild-type products are digested into 88 and 82 bp (DJ2, DJ3, DJ4, DJ5, DJ6 and control). The 2302(C→T) mutant products are not cleaved (DJ1, DJ2 DJ4 and DJ5). This shows that DJ1 is homozygous and DJ2, DJ4 and DJ5 are heterozygous for the mutation. The 100 bp ladder marker was run in lane M.
cells that have developed the other phenotype associated with cMOAT loss, failure to transport certain conjugated drugs.
MATERIALS AND METHODS

Subjects
Four patients were analyzed in this study. Patients DJ4 and DJ5 are brothers and were diagnosed as having DJS by their serum bilirubin concentration (1.3 and 1.3 mg/dl for T-bilirubin and 0.8 and 0.8 mg/ml for D-bilirubin, respectively) and co-proporphyrin retention (94.5 and 93.6% for urinary co-proporphyrin I, respectively) (21) . Other laboratory findings in DJ4 and DJ5 were as follows (21): hemoglobin concentration, 88 and 95 g/l; red cell count, 303×10 4 and 278×10 4 /mm 3 , respectively. Urinalysis showed an increased excretion of urobilinogen. Serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, γ-glutamyltranspeptidase, lactate dehydrogenase and α-fetoprotein were normal. Serum antibody titers showed no evidence of infection with rubella virus, cytomegalovirus, hepatitis B virus or herpes simplex. Hepatobiliary scintigraphy of DJ4 showed gastrointestinal excretion, without visualization of the extrahepatic biliary ducts. Abdominal sonography showed a homogeneously enlarged liver with a normal-sized biliary tree and portal veins. The gall bladder was visible. Hepatobiliary scintigraphy of DJ5 showed gastrointestinal excretion, and the extrahepatic biliary ducts were visualized. Abdominal sonography showed a liver of normal size with a normal biliary tree and portal veins. The gall bladder was visible. Menghini needle liver biopsy of DJ4 showed a specimen that was not dark Fig. 1 for the region amplified) was used to amplify the cDNA from peripheral blood leukocytes. A single RT-PCR product of 500 bp was amplified from DJ2, DJ6 and control. In contrast, a smaller fragment of 332 bp was amplified mainly from DJ3, DJ4 and DJ5. This mutation has been designated as 2272del168. The full-length band is faint in DJ3, DJ4 and DJ5, probably because unequal amplification was due to the size of each template and/or the formation of heteroduplexes resulting in shorter products. Analysis of the PCR product of each subject is shown below the corresponding symbols in the pedigree. Closed and shaded symbols show the 2302(C→T) and the deletion mutation 2272del168, respectively. (b) Restriction digestion analysis of the RT-PCR products amplified from peripheral blood leukocytes by the F primer pair (see Materials and Methods and Fig. 1 ) in DJ4, DJ5 and their family members. RT-PCR products of 404 bp were digested with AciI and electrophoresed on 3% agarose gel. There is an AciI site in the normal control sequence, providing fragments of 82 and 322 bp (DJ3, DJ6 and control). The single base substitution of nucleotide 2302 prevents digestion. A faint 404 bp band in the DJ3 and DJ6 is a product of incomplete digestion. The 200 bp band detected in DJ6 was also detected in some control samples and no alteration in these exon-intron boundaries was detected. It could be a product of alternative splicing which occurs rarely in peripheral blood leukocytes.
greenish. On light microscopic examination of DJ4, the liver showed a normal lobular pattern without inflammatory change or fibrosis. Abnormal pigment granules were seen in the hepatocytes, showing a positive reaction for Fontana-Masson and melanin stains. Macrovesicular fatty changes were also observed in the hepatocytes. Light microscopic examination of the liver from DJ5 showed that most of the hepatocytes contained pigment granules. Macrovesicular fatty droplets were also observed in the hepatocytes. Characteristic lysosomal pigment granules were observed in the cytoplasm of the hepatocytes of DJ5 by electron microscopy.
DJ2, DJ3 and DJ6 are a father, mother and sister, with DJ2 and DJ3 diagnosed as carriers of DJS by co-proporphyrin retention (42.1 and 43.5% for urinary co-proporphyrin I, respectively) (21) . The ages and sex of DJ2, DJ3, DJ4, DJ5 and DJ6 are 31, male; 28, female; 7, male; 4, male and 0.5, female, respectively. DJ2, DJ3, DJ4, DJ5 and DJ6 are members of a single family and DJ1 and DJ7 are member of other families; DJ1 and DJ7 were diagnosed as having DJS by their serum bilirubin concentration (see Results and Discussion) and pigmentation in liver. DJ1 is a 51 year old male and his T-bilirubin level is 5.0 mg/dl. DJ7 is a 46 year old male and his T-and D-bilirubin level are 5.2 and 3.8 mg/dl, respectively.
RT-PCR
The sequences of the 12 pairs of primer used for RT-PCR-sequencing analysis were as follows, with the nucleotide numbers from the translation start site for each amplified region indicated in parentheses: A(-28 to 513), 5′GTCTTTGTTCCAGACG-CAGTC3′ and 5′GGAGATGAAGAACAGGCAGG3′; B(449-876), 5′TGATCCGGACACTCTTACAGG3′ and 5′AACAT-CTTCCAGGACAAGGG3′; C(819-1303), 5′GCCTGGCTTGA-ACAAGAATC3′ and 5′TCACATCCATGAGCTTCTGG3′; D(1228-1715), 5′TTGGCCAGGAAGGAGTACAC3′ and 5′TTGTTGCTATCCACCAGGAC3′; E(1601-2067), 5′AGAAC-CTGCTGGCCTTTAGTC3′ and 5′TTCCATTTCTCCCAG-CATG3′; F(1980-2383), 5′CATTATGGCAGGCCAACTTG3′ and 5′CATGAGCATCCACTGCAGAC3′; G(2251-2750), 5′TTGGC-TGAGATTGGAGAGAAG3′ and 5′GAACTGCGGCTAAGT-GTTCG3′; H(2665-3140), 5′TCCAGTGTGGAAGAGATCCC3′ and 5′AAGGCACTCCAGAAATGTGC3′; I(3054-3553), 5′TCA-GAGGGACATGAGAGTTGG3′ and 5′GTTTCAGAAATCGC-TGCTGG3′; J(3420-3904), 5′TTATGTGTCTACCTCCCGCC3′ and 5′ACTGGATCTTGCCTTTGCTG3′; K(3801-4226), 5′GG-CTGTTGAGCGAATAACTG3′ and 5′GCCTTCCAAATCTC-CTCATC3′; L(4164-4784), 5′TGGAAGCCTGAGGATGAATC3′ and 5′TGGGTAGTAGGTTCATGGGTG3′. The nucleotide sequence corresponding to the region amplified by primer pairs E, F and G where we found mutations is also presented as Figure 1 . Total RNA from peripheral blood leukocytes and liver tissue of DJS patients was isolated using the ISOGEN (Nippongene Co., Tokyo, Japan). First-strand synthesis from total RNA was performed using random hexanucleotide primers and MMLV reverse transcriptase (Gibco BRL, Gaithersburg, MD). The single-stranded cDNA was PCR amplified with 2 pmol of the forward and reverse primers described above using AmpliTaqGold™ DNA polymerase (Perkin Elmer, Tokyo, Japan). For PCR, 40 cycles of denaturation (94_C for 30 s), annealing (60_C for 30 s) and extension (72_C for 45 s) were performed. The PCR products were sequenced directly or after subcloning into pMOSBlue vector (Amersham, Buckinghamshire, UK).
Sequencing and identification of mutations
In order to avoid PCR artifacts, we sequenced at least 10 subclones for each sample or sequenced PCR products directly, using a DyeDeoxy Terminator Cycle Sequencing kit (Applied Biosystems, Tokyo, Japan) and a DNA sequencing system (model 373S, Applied Biosystems). Both sense and antisense strands were sequenced for confirmation.
Amplification of genomic DNA
Genomic DNAs were prepared from either peripheral blood leukocyte cells or liver tissue (DJ7) following standard methods. The nucleotide sequences of the primers used to amplify the genomic fragments containing each mutation were as follows (the region to which these primers correspond are described parentheses: gFG5′, 5′TTAGGAGATGGAGCCAAGATTC3′ (intron at the beginning of the cDNA G fragment, see above); gFG3′, 5′CATGAGCATCCACTGCAGAC3′ (F and G fragments of cDNA); gE5′, 5′ AAGGATTGGCTTAGGAGGC3′ (intron at the beginning of the cDNA E fragment); gE3′, 5′AGTCATTCTG-GACTCCAAGG3′ (intron at the end of the cDNA E fragment).
